MSI-H only
Quiénes somos
EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1)
MAQ-001 in Patients With Advanced Solid Tumors
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Estudio para evaluar INCB099280 en participantes con tumores sólidos seleccionados que no han recibido ningún inhibidor de los puntos de control inmunitarios.
Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
